Scientific publications

References

NSC-Reconstruct (Novel strategies for cell-based neural reconstruction)

  • Barker, RA. et al. (2024) The history and status of dopamine cell therapies for Parkinson's disease. Bioessays. 46(12)
  • Berg, LJ. et al. (2024) Human neural stem cells directly programmed from peripheral blood show functional integration into the adult mouse brain. Stem Cell Res Ther. 15(1):488.
  • Bocchi R. et al (2025) Astrocyte heterogeneity reveals region-specific astrogenesis in the white matter. Nat Neurosci. doi: 10.1038/s41593-025-01878-6.
  • Cattaneo E. et al. (2024) Brain cholesterol therapy for Huntington's disease - Does it make sense? Clin Transl Med. 14(7):e1746.
  • Cattaneo E. et al. (2025) Stem Cell Revolutions: An alliance for Parkinson's disease driven by European Commission consortia. Pharmacol Res.212:107569.
  • Christiansen, JR. et al. (2024) Clinical translation of pluripotent stem cell-based therapies: successes and challenges. Development.151(7):dev202067.
  • Fiorenzano, A. et al. (2024) TARGET-seq: Linking single-cell transcriptomics of human dopaminergic neurons with their target specificity. Proc Natl Acad Sci U S A.121(47):e2410331121.
  • Fogli, M. et al. (2024) Dynamic spatiotemporal activation of a pervasive neurogenic competence in striatal astrocytes supports continuous neurogenesis following injury. Stem Cell Reports.19(10):1432-1450.
  • Knöbel, S. et al. (2024) Scaling of cell and gene therapies to population. Handb Clin Neurol. 205:145-154.
  • Kojima, R. et al. (2024) Secretome Analyses Identify FKBP4 as a GBA1-Associated Protein in CSF and iPS Cells from Parkinson's Disease Patients with GBA1 Mutations. Int J Mol Sci. 25(1):683.
  • Libé-Philippot, B. et al. (2024) Synaptic neoteny of human NSC-Reconstruct (874758) - Periodic Technical Report - PART B – Period 4 9 cortical neurons requires species-specific balancing of SRGAP2-SYNGAP1 cross-inhibition. Neuron. 112(21):3602-3617.
  • Natarajan, P. et al. (2025) Single Cell Deletion of the Transcription Factors Trps1 and Sox9 in Astrocytes Reveals Novel Functions in the Adult Cerebral Cortex. Glia 73(4):737-758.

AdCAR-AML (Adapter CAR T cells for the treatment of patients with relapsed/refractory acute myeloid leukemia)

  • Nixdorf, D. et al. (2023) Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia 37, 1298–1310.
  • Werchau, N. et al. (2022) Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells. Oncoimmunology. 11(1):2140534.
  • Seitz, C. M. et al. (2021) Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. Oncoimmunology. 10(1):2003532.
  • Atar, D. et al. (2022) Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas Biomedicines. 10(10):2420.
  • Önder, C. E. (2023) Precision Immunotherapy Utilizing Adapter CAR-T Cells (AdCAR-T) in Metastatic Breast Cancer Leads to Target Specific Lysis. Cancers (Basel). 16(1):168.

OptiCAN (Optimized T cells for personalized immunotherapy for solid tumors)

  • Nilsson, L. M. et al. (2020) Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models. Gastro Hep Advances. 1: P1037–1048.
  • Karlsson, J. W. (2024) Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases. Elife. 12:RP91705. PMID: 39312285; PMCID: PMC11419671.

CD20 CAR-TIME (CD20 CAR transduced T cells for individualized melanoma therapy)

  • Aleksandrova, K. et al. (2024) Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. Front. Immunol. 15:1328368.
  • Aleksandrova, K. et al. (2019) Functionality and Cell Senescence of CD4/ CD8-Selected CD20 CAR T Cells Manufactured Using the Automated CliniMACS Prodigy® Platform. Transfus. Med. Hemother. 46: 47–54.
  • Zuther K et al. (2017) Individualisierte Therapie mit CAR-exprimierenden Immunzellen, Journal Onkologie 2/2017
  • Lock D et al. (2017) Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use. Hum Gene Ther. 28(10):914-925.
  • Hadenfeld, et al. (2016) Automatisierung für die personalisierte Krebstherapie. Biospektrum. 22: 496–498.
  • Priesner, C. et al. (2016) Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products; Human Gene Therapy. 27(10):860-869.

T2EVOLVE (Accelerating development and improving access to CAR and TCR-engineered T cell therapy in Europe)

  • Lock, D. et al. (2022) Automated, scaled, transposon-based production of CAR T cells. J. Immunother. Cancer. 10: e005189.
  • Ammar,D. et al. (2023) Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations; Front Immunol 14:1280826. eCollection 2023.
  • Navarro S. et al. (2024) Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection. Mol Ther. 2025 Mar 5;33(3):847-865. doi: 10.1016/j.ymthe.2024.11.017. Epub 2024 Nov 12. PMID: 39533710; PMCID: PMC11897765.
  • De Angelis B. et al. (2025) European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring. Front Immunol. 2025 Apr 24;16:1567582. doi: 10.3389/fimmu.2025.1567582. PMID: 40342422; PMCID: PMC12058815.
  • Ammar D. et al. (2025) Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. Cytotherapy. Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe - ScienceDirect

REAP (Revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacoustic tomography)

  • Liu, M. et al.(2021) REAP: revealing drug tolerant persister cells in cancer using contrast enhanced optical coherence and photoacoustic tomography. J. Phys. Photonics. 3: 021001.

CARAT (Chimeric antigen receptors for advanced therapies)

  • Alzubi, J. et al. (2020) Automated generation of gene-edited CAR T cells at clinical scale. Mol. Ther. Methods Clin. Dev. 20: 379–388.
  • Arcangeli, S. et al. (2020) Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. Front. Immunol. 11: 1217.
  • Radek, C. et al. (2019) Vectofusin-1 improves transduction of primary human cells with diverse retroviral and lentiviral pseudotypes, enabling robust, automated closed-system manufacturing. Hum. Gene Ther. 30: 1477–1493.

DEEPINSIGHT (Preclinical micro-endoscopy in tumors: Targeting metastatic intravasation and resistance)

  • Bakker, G.-J. et al. (2022) Intravital deep-tumor single-beam 3-photon, 4-photon, and harmonic microscopy. Elife. 11: e63776.

SARS Therapy (Therapeutic approach with SARS-CoV-2-specific T cells for the treatment of severely ill COVID-19 patients)

  • Bonifacius, A. et al. (2022) Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. Front. Bioeng. Biotechnol. 10: 867042.

TraCAR (Non-invasive imaging of pharmacokinetics and optimization of CAR T cell therapies of solid tumors)

  • Pfeifer, R. et al. (2022) A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level. Theranostics. 12: 4834–4850.

ImmunePredict (Development of new predictive markers for response toimmune checkpoint inhibitors of solid tumors)

  • Brinkmann, E.-M. et al. (2021) Advanced high dynamic range fluorescence microscopy with Poisson noise modeling and integrated edge-preserving denoising. J. Phys. Commu. 5: 075016.

RETI-IM (Retinal imaging techniques for early diagnosis of neurodegenerative and neuroimmunological diseases)

  • Bremer, D. et al. (2016) Longitudinal Intravital Imaging of the Retina Reveals Long-term Dynamics of Immune Infiltration and Its Effects on the Glial Network in Experimental Autoimmune Uveoretinitis, without Evident Signs of Neuronal Dysfunction in the Ganglion Cell Layer. Front. Immunol. 23: 7: 642.
  • Rakhymzhan, A. et al (2020) Coregistered Spectral Optical Coherence Tomography and Two-Photon Microscopy for Multimodal Near-Instantaneous Deep-Tissue Imaging. Cytometry A. 97: 515–527.

GD2-IL18 CART (Phase I clinical trial of safety, dose-finding, and feasibility of adoptive T-cell therapy with GD2-IL18 CART in patients with relapsed or refractory GD2-positive solid tumors)

  • Fischer-Riepe, L. et al. (2024) Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clin Cancer Res. 30(16):3564-3577. PMID: 38593230.

AspecT NMO (Measuring autoantigen-specific T cells as new diagnostic sensors and therapeutic targets in neuromyelitis optica)

  • Saggau, C. et al. (2024) Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases. Immunity. S1074-7613(24)00404-7. Epub ahead of print. PMID: 39226901.

CellEurope project

  • Reis, M. (2016). Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications. Front Immunol. 14;7:500. PMID: 27895644; PMCID: PMC5107577.

The ONE Study

  • Sawitzki, B. et al. (2020) Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 395(10237):1627-1639. doi: 10.1016/S0140-6736(20)30167-7. Erratum in: Lancet. 2020 Jun 27;395(10242):1972. doi: 10.1016/S0140-6736(20)31419-7. PMID: 32446407; PMCID: PMC7613154.

SARS Diagnostics (SARS-CoV-2-specific T cell diagnostics for monitoring long-term immunity as chance in the Corona crisis)

  • Dörnte C. et al. (2025) Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Courses. Eur J Immunol. 2025 Apr;55(4):e202451497. doi: 10.1002/eji.202451497. PMID: 40259456; PMCID: PMC12012228.

ELICIT (Advanced light sheet microscopy for high-throughput clinical analysis of immune cell infiltration of tumor samples)

  • Pinkert-Leetsch D. et al. (2025) First application of three-dimensional light sheet fluorescence microscopy to human testicular tumors: New perspectives in histopathology. Andrology. 2025 Feb 12. doi: 10.1111/andr.70009. Epub ahead of print. PMID: 39936385.

Partner with us

Are you looking for a reliable partner for your next grant project?

Get in touch with our Grant Management Team to discuss your ideas.